Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

Fig. 3

Kaplan–Meier analyses of overall survival and disease-free survival based on carboplatin administration and pathological complete response status. A DFS according to pathologic complete response status p = 0.002. B OS according to pathologic complete response status p < 0.001. C OS according to carboplatin use p = 0.570. D DFS according to carboplatin use p = 0.482

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us